The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

Initial results with gemcitabine (Gem) and mitomycin C (MMC) appeared promising but shortages in MMC led to the need to substitute docetaxel (Doce) for MMC to create Gem/Doce. Both were developed by ...

NuCana (NCNA) announced that initial data from the ongoing Phase 1b/2 modular study investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors ...

Aims: To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer. Patients & methods: The MTD was determined from dose ...

Get detailed information on Docetaxel, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Optune Lua, combined with immunotherapy or docetaxel, extends overall survival by 3.3 months. Optune Lua is a portable device that produces alternating electric fields known as tumor-treating ...

Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival (rPFS) in docetaxel-pretreated patients. Abiraterone acetate plus ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

▎药明康德内容团队编辑BeyondSpring今天公布研究者发起的临床2期试验KeyPelms-004的最新数据。分析显示，接受其在研小分子药物plinabulin、多西他赛（docetaxel）与PD-1抑制剂pembrolizumab三联疗法治疗 ...

BRFS at 48 weeks, defined as a prostate-specific antigen (PSA) value ≤0.2 ng/mL, increased from 16% with ADT and docetaxel to 41% with the addition of 177 Lu-PSMA-617 (OR 3.88, 95% CI 1.61-9.38).

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

Docetaxel is the current standard of care for NSCLC patients without targetable alterations who progress on PD-(L)1 inhibitor-based therapy, however, it is associated with modest clinical benefit ...